Claims for Patent: 10,610,125

Summary for Patent: 10,610,125

Title:	Methods and compositions for cell-proliferation-related disorders
Abstract:	Methods of treating and evaluating subjects having neoactive mutants are described herein.
Inventor(s):	Dang; Lenny (Boston, MA), Fantin; Valeria (Burlingame, CA), Gross; Stefan (Brookline, MA), Jang; Hyun Gyung (Waltham, MA), Jin; Shengfang (Newton, MA), Salituro; Francesco G. (Marlborough, MA), Saunders; Jeffrey O. (Lincoln, MA), Su; Shin-San Michael (Boston, MA), Yen; Katharine (Wellesley, MA)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/589,615
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,610,125
Patent Claims:	1. A method of treating a subject having acute myelogenous leukemia (AML) characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG), the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of said mutant IDH1 or mutant IDH2. 2. The method of claim 1, wherein the inhibitor binds to IDH1R132X or IDH2R172X and inhibits the ability to convert alpha-ketoglutarate to 2-HG. 3. The method of claim 1, wherein the cancer is characterized by an IDH1 mutation. 4. The method of claim 3, wherein the IDH1 mutation is an IDH1R132X mutation. 5. The method of claim 3, wherein the IDH1 mutation is selected from R132H, R132C, R132S, R132G, R132L, and R132V. 6. The method of claim 1, wherein the cancer is characterized by an IDH2 mutation. 7. The method of claim 6, wherein the IDH2 mutation is an IDH1R172X mutation. 8. The method of claim 6, wherein the IDH2 mutation is selected from R172K, R172M, R172S, R172G, and R172W. 9. The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected in a sample obtained from the subject. 10. The method of claim 9, wherein the sample comprises tissue or bodily fluid. 11. The method of claim 1, wherein the mutant IDH1 or mutant IDH2 is detected by sequencing a nucleic acid from an affected cell that encodes the relevant amino acid(s) from the mutant IDH1 or mutant IDH2. 12. The method of claim 11, wherein the sequencing is performed by polymerase chain reaction (PCR).